AIA Group Ltd grew its holdings in CME Group Inc. (NASDAQ:CME - Free Report) by 17.8% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 16,645 shares of the financial services provider's stock after buying an additional 2,510 shares during the quarter. AIA Group Ltd's holdings in CME Group were worth $4,416,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in CME. Price T Rowe Associates Inc. MD increased its position in CME Group by 89.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,280,785 shares of the financial services provider's stock worth $1,923,047,000 after purchasing an additional 3,921,278 shares during the period. GAMMA Investing LLC increased its position in CME Group by 32,941.0% in the first quarter. GAMMA Investing LLC now owns 1,858,887 shares of the financial services provider's stock worth $493,144,000 after purchasing an additional 1,853,261 shares during the period. Nuveen LLC bought a new position in CME Group during the first quarter worth about $218,842,000. Egerton Capital UK LLP boosted its holdings in CME Group by 79.4% during the first quarter. Egerton Capital UK LLP now owns 1,730,194 shares of the financial services provider's stock worth $459,003,000 after buying an additional 765,773 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in CME Group by 29.9% during the first quarter. Massachusetts Financial Services Co. MA now owns 2,818,590 shares of the financial services provider's stock worth $747,744,000 after buying an additional 648,591 shares during the last quarter. 87.75% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at CME Group
In related news, General Counsel Jonathan L. Marcus sold 390 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $277.50, for a total transaction of $108,225.00. Following the completion of the sale, the general counsel directly owned 6,708 shares in the company, valued at $1,861,470. This represents a 5.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Charles P. Carey sold 500 shares of the stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $265.35, for a total value of $132,675.00. Following the completion of the transaction, the director owned 4,900 shares of the company's stock, valued at $1,300,215. This represents a 9.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,750 shares of company stock worth $1,576,294 over the last quarter. 0.30% of the stock is currently owned by company insiders.
Analyst Ratings Changes
A number of equities analysts have issued reports on CME shares. Piper Sandler raised their target price on CME Group from $283.00 to $296.00 and gave the stock an "overweight" rating in a report on Tuesday, July 15th. Morgan Stanley raised their target price on CME Group from $301.00 to $304.00 and gave the stock an "overweight" rating in a report on Thursday, April 24th. Erste Group Bank cut CME Group from a "strong-buy" rating to a "hold" rating in a report on Saturday, May 24th. Barclays set a $298.00 price objective on CME Group and gave the company an "equal weight" rating in a report on Thursday, July 24th. Finally, UBS Group reiterated a "neutral" rating and set a $305.00 price objective on shares of CME Group in a report on Thursday, July 24th. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $261.93.
Get Our Latest Stock Report on CME
CME Group Stock Performance
Shares of CME stock traded down $9.87 during trading on Tuesday, reaching $275.88. 2,741,043 shares of the company's stock were exchanged, compared to its average volume of 2,052,923. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $99.42 billion, a PE ratio of 26.71, a PEG ratio of 5.07 and a beta of 0.44. CME Group Inc. has a twelve month low of $204.16 and a twelve month high of $290.79. The firm's fifty day moving average price is $275.61 and its 200-day moving average price is $266.55.
CME Group (NASDAQ:CME - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.91 by $0.05. The business had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.68 billion. CME Group had a return on equity of 14.60% and a net margin of 58.48%. The firm's revenue was up 10.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.56 EPS. As a group, sell-side analysts anticipate that CME Group Inc. will post 10.49 EPS for the current year.
CME Group Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 25th. Investors of record on Tuesday, September 9th will be given a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a dividend yield of 1.8%. CME Group's dividend payout ratio is currently 48.40%.
About CME Group
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
See Also
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
MarketBeat All Access